Enliven Therapeutics Inc. (ELVN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.59B
Last updated: Nov 17, 2026 at 11:05 AM ET
Enliven Therapeutics Inc. (ELVN) Earnings: Report Dates and Results
Enliven Therapeutics (ELVN) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Enliven Therapeutics reported EPS of -$0.36, above the -$0.48 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ELVN has an expected report date of Mar 1, 2027.
Earnings History
Of the 27 quarters below that had an estimate, ELVN beat 18 and missed 9. The widest gap in the table came in the quarter ended Mar 31, 2020, when EPS landed 486.39% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.36 | -$0.48 | -$0.52 - -$0.38 | +25.00% | Beat | N/A | 8 | 0 up, 2 down | Nov 5, 2026 |
| Jun 30, 2026 | -$0.49 | -$0.38 | -$0.40 - -$0.29 | -28.95% | Miss | N/A | 3 | N/A | Aug 5, 2026 |
| Mar 31, 2026 | -$0.38 | -$0.41 | -$0.51 - -$0.31 | +7.32% | Beat | N/A | 2 | 0 up, 0 down | May 7, 2026 |
| Dec 31, 2025 | -$0.48 | -$0.38 | N/A | -27.05% | Miss | N/A | 2 | 0 up, 0 down | Mar 3, 2026 |
| Sep 30, 2025 | -$0.32 | -$0.46 | -$0.48 - -$0.45 | +30.43% | Beat | N/A | 2 | 0 up, 0 down | Nov 12, 2025 |
| Jun 30, 2025 | -$0.49 | -$0.42 | -$0.47 - -$0.37 | -16.67% | Miss | N/A | 2 | 0 up, 0 down | Aug 13, 2025 |
| Mar 31, 2025 | -$0.57 | -$0.50 | N/A | -14.00% | Miss | N/A | N/A | 0 up, 0 down | May 14, 2025 |
| Dec 31, 2024 | -$0.46 | -$0.52 | N/A | +11.11% | Beat | N/A | N/A | 0 up, 0 down | Mar 13, 2025 |
| Sep 30, 2024 | -$0.48 | -$0.50 | -$0.55 - -$0.44 | +4.00% | Beat | N/A | 8 | 0 up, 0 down | Nov 13, 2024 |
| Jun 30, 2024 | -$0.41 | -$0.56 | -$0.65 - -$0.49 | +26.79% | Beat | N/A | 6 | 0 up, 0 down | Aug 13, 2024 |
| Mar 31, 2024 | -$0.54 | -$0.57 | -$0.58 - -$0.55 | +5.26% | Beat | N/A | 3 | 0 up, 0 down | May 14, 2024 |
| Dec 31, 2023 | -$0.47 | -$0.54 | -$0.56 - -$0.51 | +12.96% | Beat | -138.8% | 4 | 0 up, 0 down | Mar 14, 2024 |
| Sep 30, 2023 | -$0.51 | -$0.47 | -$0.53 - -$0.44 | -8.51% | Miss | N/A | 3 | 0 up, 0 down | Nov 9, 2023 |
| Jun 30, 2023 | -$0.41 | -$0.40 | N/A | -2.50% | Miss | N/A | N/A | N/A | Aug 10, 2023 |
| Mar 31, 2023 | -$0.80 | -$0.52 | N/A | -53.85% | Miss | N/A | N/A | N/A | May 11, 2023 |
| Dec 31, 2022 | $1.21 | -$0.79 | N/A | +253.94% | Beat | N/A | N/A | N/A | Feb 10, 2023 |
| Sep 30, 2022 | -$0.72 | -$1.00 | N/A | +28.00% | Beat | N/A | N/A | N/A | Oct 25, 2022 |
| Jun 30, 2022 | -$1.76 | -$2.05 | N/A | +14.15% | Beat | N/A | N/A | N/A | Aug 3, 2022 |
| Mar 31, 2022 | -$2.24 | -$2.31 | N/A | +3.03% | Beat | N/A | N/A | N/A | May 6, 2022 |
| Dec 31, 2021 | -$2.12 | -$3.00 | N/A | +29.33% | Beat | N/A | N/A | N/A | Mar 15, 2022 |
| Sep 30, 2021 | -$2.20 | -$3.38 | N/A | +34.91% | Beat | N/A | N/A | N/A | Nov 9, 2021 |
| Jun 30, 2021 | -$2.96 | -$3.20 | N/A | +7.50% | Beat | N/A | N/A | N/A | Aug 6, 2021 |
| Mar 31, 2021 | -$2.32 | -$3.34 | N/A | +30.54% | Beat | N/A | N/A | N/A | May 11, 2021 |
| Dec 31, 2020 | -$2.24 | -$3.35 | N/A | +33.13% | Beat | N/A | N/A | N/A | Mar 5, 2021 |
| Sep 30, 2020 | -$2.88 | -$3.21 | N/A | +10.28% | Beat | N/A | N/A | N/A | Nov 5, 2020 |
| Jun 30, 2020 | -$2.36 | -$2.25 | N/A | -4.89% | Miss | N/A | N/A | N/A | Aug 14, 2020 |
| Mar 31, 2020 | -$17.24 | -$2.94 | N/A | -486.39% | Miss | N/A | N/A | N/A | May 7, 2020 |
| Dec 31, 2019 | -$0.68 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 11, 2020 |
| Sep 30, 2019 | -$0.32 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Oct 8, 2019 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.86, after -$1.89 the year before. It was -$1.00 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.86 | N/A |
| Dec 31, 2024 | -$1.89 | N/A |
| Dec 31, 2023 | -$2.19 | N/A |
| Dec 31, 2022 | -$3.51 | N/A |
| Dec 31, 2021 | -$9.60 | N/A |
| Dec 31, 2020 | -$24.72 | N/A |
| Dec 31, 2019 | -$1.00 | N/A |
Frequently Asked Questions About ELVN
When is Enliven Therapeutics's next earnings date?
Enliven Therapeutics's next earnings report is expected for Mar 1, 2027.
Did ELVN beat earnings estimates last quarter?
Yes. Enliven Therapeutics reported EPS of -$0.36 for the quarter ended Sep 30, 2026, above the -$0.48 estimate, a 25.00% surprise.
What EPS do analysts expect from ELVN next quarter?
The consensus EPS estimate for Enliven Therapeutics for the quarter ending Dec 31, 2026 is -$0.53 from 16 analysts, with estimates from -$0.68 to -$0.42.
How often does ELVN beat earnings estimates?
Enliven Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -1.60%.
ELVN pages: Overview, Earnings, Forecast, Financials, Competitors